Hamburg

• A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy … Ended
  2022-501382-49-00 5 2017-03-07 Triple Negative Breast Cancer (TNBC)
• A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexametha … Ended
  2024-511967-26-00 5 2016-11-21 AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)
• Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of … Ended
  2024-512934-14-00 5 2016-11-07 advanced or metastatic adenocarcinoma of the stomach or gastroesophage
• Pembrolizumab in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma Ended
  2023-507294-18-00 5 2016-09-16 Metastatic renal cell carcinoma
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea … Ended
  2024-511235-10-00 5 2016-07-25 Generalized mantle cell Lymphoma
• HD21 Ended
  2024-518022-33-00 5 2016-07-15 Advanced Stage of Hodgkin Lymphoma
• A study of nivolumab or placebo in patients following removal of their esophageal or gastroesophageal junction cancer. Ended
  2023-509360-24-00 5 2016-06-16 Subjects with resected adenocarcinoma or squamous cell carcinoma esoph
• A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af … Ended
  2023-509137-39-00 5 2015-11-06 Stage IB (T ≥ 4 cm), II and IIIA NSCLC
• A Phase 3 Study of Nivolumab plus Ipilimumab Versus Sunitinib in untreated Subjects with Advanced or Metastatic Renal Cell Carcinoma (RCC) Ended
  2023-504761-23-00 5 2014-11-19 Advanced or metastatic renal cell carcinoma
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5) Ended
  2022-501106-35-00 5 Obesity Overweight
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan … Ended
  2023-506487-13-00 5 Hormone receptor-positive, her2-negative advanced/metastatic breast ca
• A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Ref … Ended
  2023-509472-42-00 5 Relapsed and/or Refractory Multiple Myeloma
• A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONS … Ended
  2024-512804-20-00 5 Metastatic Colorectal Cancer
• A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart i … Ended
  2024-512986-15-00 4 Sjögren’s Disease
• Surgical or radiotherapeutic intervention concerning large singular stable to progressive metastases in patients with BRAFV600-mutated melan … Ended
  2024-516073-74-00 6 Unresectable or metastatic melanoma with a BRAF V600 mutation (inopera
• Durability of Immunity induced by the Ebolavirus Vaccine VSV-EBOV and Assessment of a Booster Dose for Pre-Exposure Prophylaxis in Individua … Ended
  2024-517352-35-00 10 Ebola virus infection
• A study to evaluate the safety and efficacy of mebendazole in combination with low-dose Ara-C in elderly patients with relapsed/refractory a … Ended
  2024-518363-36-00 4 relapsed/refractory acute myeloid leukemia
• A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced melanoma Ended
  2025-522054-40-00 4 Previously treated advanced melanoma

Showing 1,081–1,098 of 1,098 trials